Adding mitomycin C to BCG as adjuvant intravesical therapy for high risk, non–muscle invasive bladder cancer: A randomised phase 3 trial (ACTRN12613000513718)
BCG+MM
This trial is Currently recruiting
Registration number ACTRN12613000513718
Program & service
This trial is being run with the Surgery service, and as part of the Urology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor Jeremy Grummet
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.